Stevens-Johnson syndrome epidemiology and demographics
|
Stevens-Johnson syndrome Microchapters |
|
Differentiating Stevens-Johnson Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Stevens-Johnson syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Stevens-Johnson syndrome epidemiology and demographics |
|
FDA on Stevens-Johnson syndrome epidemiology and demographics |
|
CDC on Stevens-Johnson syndrome epidemiology and demographics |
|
Stevens-Johnson syndrome epidemiology and demographics in the news |
|
Blogs on Stevens-Johnson syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Stevens-Johnson syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]
Overview
SJS is a rare condition, with a reported incidence of around 2-7 per 1000,000 people per year and a mean mortality rate of 4.8 percent. It is seen in patients of all age groups but particularly in children and young adults. Females are more commonly affected than males
Epidemiology and Demographics
Incidence
- The incidence of SJS is approximately 2-7 per 1000,000 individuals per year.[1]
- The incidences of SJS, SJS-TEN, and TEN were found to be a mean 5.3, 0.8, and 0.4 cases per million children per year in the US[2]
- The mean estimated incidences of SJS, SJS/TEN, and TEN were found to be 9.2, 1.6, and 1.9 per million adults per year in the US[3]
Case-fatality rate/Mortality rate
- Between years 2009-2012, the Mean adjusted mortality was 4.8% for SJS, 19.4% for SJS/TEN, and 14.8% for TEN[4]
Age
- Patients of all age groups may develop SJS.
Race
- The incidence of SJS might be higher in Non White/Multiracial people as compared to White"Redirecting".
Gender
- Women are more commonly affected by SJS than males"Redirecting"..
References
- ↑ Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M; et al. (1991). "A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures". Arch Dermatol. 127 (6): 831–8. PMID 2036028.
- ↑ Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI (2017). "Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States". J Am Acad Dermatol. 76 (5): 811–817.e4. doi:10.1016/j.jaad.2016.12.024. PMC 5502094. PMID 28285784.
- ↑ Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). "Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults". J Invest Dermatol. 136 (7): 1387–1397. doi:10.1016/j.jid.2016.03.023. PMID 27039263.
- ↑ Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). "Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults". J Invest Dermatol. 136 (7): 1387–1397. doi:10.1016/j.jid.2016.03.023. PMID 27039263.